Comparing ANI Pharmaceuticals (ANIP) & Biohaven Pharmaceutical Holding Co (BHVN)

ANI Pharmaceuticals (NASDAQ: ANIP) and Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitabiliy, valuation, dividends and risk.

Earnings and Valuation

This table compares ANI Pharmaceuticals and Biohaven Pharmaceutical Holding Co’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals $144.70 million 3.50 $58.86 million $0.46 94.48
Biohaven Pharmaceutical Holding Co N/A N/A -$72.14 million N/A N/A

ANI Pharmaceuticals has higher revenue and earnings than Biohaven Pharmaceutical Holding Co.

Institutional and Insider Ownership

56.0% of ANI Pharmaceuticals shares are owned by institutional investors. 31.6% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for ANI Pharmaceuticals and Biohaven Pharmaceutical Holding Co, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 1 2 0 2.67
Biohaven Pharmaceutical Holding Co 0 0 5 0 3.00

ANI Pharmaceuticals presently has a consensus price target of $65.33, suggesting a potential upside of 50.33%. Biohaven Pharmaceutical Holding Co has a consensus price target of $31.75, suggesting a potential upside of 30.98%. Given ANI Pharmaceuticals’ higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Biohaven Pharmaceutical Holding Co.

Profitability

This table compares ANI Pharmaceuticals and Biohaven Pharmaceutical Holding Co’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals 3.35% 22.70% 11.48%
Biohaven Pharmaceutical Holding Co N/A N/A -172.50%

Summary

ANI Pharmaceuticals beats Biohaven Pharmaceutical Holding Co on 8 of the 10 factors compared between the two stocks.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.